Clinical Trial Update: Effect of Aspergillus Niger Prolyl Endoprotease (AN-PEP) Enzyme on the Effects of Gluten Ingestion in Patients With Coeliac Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating whether the Aspergillus niger prolyl endoprotease (AN-PEP) enzyme can mitigate gluten-related effects in people with celiac disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Celiac Disease

Drugs mentioned

• AN-PEP (Aspergillus niger prolyl endoprotease)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Celiac Disease | Phase 1, Phase 2 | Status: COMPLETED